[go: up one dir, main page]

TNSN98065A1 - Un sel nouveau - Google Patents

Un sel nouveau

Info

Publication number
TNSN98065A1
TNSN98065A1 TNTNSN98065A TNSN98065A TNSN98065A1 TN SN98065 A1 TNSN98065 A1 TN SN98065A1 TN TNSN98065 A TNTNSN98065 A TN TNSN98065A TN SN98065 A TNSN98065 A TN SN98065A TN SN98065 A1 TNSN98065 A1 TN SN98065A1
Authority
TN
Tunisia
Prior art keywords
salt
new salt
hemisulfate salt
hemisulfate
cyclopropylamino
Prior art date
Application number
TNTNSN98065A
Other languages
English (en)
Inventor
Francis Jones Martin
John Wallis Christopher
Couper Brodie Alastair
Frederick Seager John
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10812407&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN98065(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of TNSN98065A1 publication Critical patent/TNSN98065A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Seasonings (AREA)

Abstract

EST DECRIT LE SEL HEMISULFATE DE (1S,4R) CIS-4 [ 2 - AMINO-6 (CYCLOPROPYLAMINO)- 9H-PURINE-9-YL] 2-CYCLOPENTENE -1-METHANOL OU UN SOLVATE DE CELUI-CI. SONT EGALEMENT DECRITES LES METHODES DE PREPARATION ET LES COMPOSES DE DEPART POUR LA REALISATION DU DIT SEL HEMISULFATE. CE SEL EST UTILE EN MEDECINE PARTICULIEREMENT POUR LE TRAITEMENT D'INFECTIONS VIRALES
TNTNSN98065A 1997-05-17 1998-04-15 Un sel nouveau TNSN98065A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9709945.1A GB9709945D0 (en) 1997-05-17 1997-05-17 A novel salt

Publications (1)

Publication Number Publication Date
TNSN98065A1 true TNSN98065A1 (fr) 2005-03-15

Family

ID=10812407

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN98065A TNSN98065A1 (fr) 1997-05-17 1998-04-15 Un sel nouveau

Country Status (50)

Country Link
US (1) US6294540B1 (fr)
EP (1) EP0983271B1 (fr)
JP (2) JP3150711B2 (fr)
KR (1) KR100521292B1 (fr)
CN (2) CN1150194C (fr)
AP (1) AP2009A (fr)
AR (2) AR015668A1 (fr)
AT (1) ATE259811T1 (fr)
AU (1) AU739953B2 (fr)
BG (1) BG64390B1 (fr)
BR (1) BRPI9809126B8 (fr)
CA (1) CA2289753C (fr)
CO (1) CO4940435A1 (fr)
DE (1) DE69821758T2 (fr)
DK (1) DK0983271T3 (fr)
DZ (1) DZ2493A1 (fr)
EA (1) EA001809B1 (fr)
EE (1) EE03924B1 (fr)
EG (1) EG23836A (fr)
ES (1) ES2214712T3 (fr)
GB (3) GB9709945D0 (fr)
GE (1) GEP20022680B (fr)
HN (1) HN1998000071A (fr)
HR (1) HRP980265B1 (fr)
HU (1) HU226563B1 (fr)
ID (1) ID24910A (fr)
IL (2) IL132793A0 (fr)
IS (1) IS2207B (fr)
JO (1) JO2032B1 (fr)
MA (1) MA26498A1 (fr)
MY (1) MY120151A (fr)
NO (1) NO324731B1 (fr)
NZ (2) NZ510622A (fr)
OA (1) OA11304A (fr)
PA (1) PA8451301A1 (fr)
PE (1) PE78799A1 (fr)
PL (1) PL189527B1 (fr)
PT (1) PT983271E (fr)
RS (1) RS49655B (fr)
SA (1) SA98190179B1 (fr)
SI (1) SI0983271T1 (fr)
SK (1) SK285159B6 (fr)
SV (1) SV1998000057A (fr)
TN (1) TNSN98065A1 (fr)
TR (1) TR199902810T2 (fr)
TW (1) TW480259B (fr)
UA (1) UA56231C2 (fr)
UY (1) UY25004A1 (fr)
WO (1) WO1998052949A1 (fr)
ZA (2) ZA984083B (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9802472D0 (en) * 1998-02-06 1998-04-01 Glaxo Group Ltd Pharmaceutical compositions
HU226998B1 (en) * 2000-11-23 2010-04-28 Richter Gedeon Nyrt Desloratadine hemisulphate, process for the preparation thereof and pharmaceutical compositions containing the same
GB0320738D0 (en) 2003-09-04 2003-10-08 Glaxo Group Ltd Novel process
EP1905772A1 (fr) * 2006-09-28 2008-04-02 Esteve Quimica, S.A. Procédé de préparation de l'abacavir
JP5334852B2 (ja) * 2006-09-28 2013-11-06 エステヴェ キミカ， エス．エー． アバカビルの製造方法
EP2085397A1 (fr) 2008-01-21 2009-08-05 Esteve Quimica, S.A. Forme cristalline d'abacavir
EP2218721A1 (fr) * 2009-02-11 2010-08-18 LEK Pharmaceuticals d.d. Nouveaux sels de sitagliptine
EP2305680A3 (fr) 2009-09-30 2011-05-18 Aurobindo Pharma Limited Nouveaux sels de (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino)-9H-purin-9-yl]-2-cyclopentene-1-méthanol
LT3494972T (lt) 2010-01-27 2024-03-12 Viiv Healthcare Company Dolutegraviro ir lamivudino kompozicija živ infekcijai gydyti
US9650346B2 (en) 2011-04-08 2017-05-16 Laurus Labs Private Ltd. Solid forms of antiretroviral compounds, process for the preparation and their pharmaceutical composition thereof
JP6391561B2 (ja) 2013-02-27 2018-09-19 国立大学法人京都大学 がんの予防または治療用医薬組成物
CN104788451A (zh) * 2014-01-21 2015-07-22 浙江九洲药业股份有限公司 一种阿巴卡韦的制备方法
CN105315280A (zh) * 2014-06-06 2016-02-10 上海迪赛诺化学制药有限公司 一种阿巴卡韦结晶体及其制备方法
US10874687B1 (en) 2020-02-27 2020-12-29 Atea Pharmaceuticals, Inc. Highly active compounds against COVID-19

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY104575A (en) * 1989-12-22 1994-04-30 The Wellcome Foundation Ltd Therapeutic nucleosides.
GB9417249D0 (en) 1994-08-26 1994-10-19 Wellcome Found A novel salt
MY115461A (en) * 1995-03-30 2003-06-30 Wellcome Found Synergistic combinations of zidovudine, 1592u89 and 3tc
EA001457B1 (ru) * 1996-06-25 2001-04-23 Глаксо Груп Лимитед Комбинации, содержащие vx478, зидовудин и/или 1592u89, для применения при лечении вич

Also Published As

Publication number Publication date
ES2214712T3 (es) 2004-09-16
PE78799A1 (es) 1999-08-31
ID24910A (id) 2000-08-31
OA11304A (en) 2003-10-22
GB2348202A (en) 2000-09-27
IS5246A (is) 1999-11-11
EE03924B1 (et) 2002-12-16
EA001809B1 (ru) 2001-08-27
ZA984083B (en) 1999-11-15
NO324731B1 (no) 2007-12-03
MY120151A (en) 2005-09-30
CO4940435A1 (es) 2000-07-24
SV1998000057A (es) 1999-03-02
PL336888A1 (en) 2000-07-17
GB2340491B (en) 2000-10-18
JO2032B1 (en) 1999-05-15
BG64390B1 (bg) 2004-12-30
CA2289753A1 (fr) 1998-11-26
CA2289753C (fr) 2007-01-23
CN100408580C (zh) 2008-08-06
TW480259B (en) 2002-03-21
GB9709945D0 (en) 1997-07-09
EE9900537A (et) 2000-06-15
GB2340491A (en) 2000-02-23
UY25004A1 (es) 2000-10-31
ATE259811T1 (de) 2004-03-15
PA8451301A1 (es) 2000-05-24
NO995622L (no) 2000-01-14
DE69821758T2 (de) 2005-01-13
DZ2493A1 (fr) 2004-06-20
NZ500865A (en) 2001-04-27
AU7765598A (en) 1998-12-11
GEP20022680B (en) 2002-04-25
HUP0002754A3 (en) 2003-01-28
NO995622D0 (no) 1999-11-16
GB9926839D0 (en) 2000-01-12
HRP980265B1 (en) 2004-10-31
EP0983271A1 (fr) 2000-03-08
DE69821758D1 (de) 2004-03-25
AR015668A1 (es) 2001-05-16
BR9809126A (pt) 2000-08-01
HK1024236A1 (en) 2000-10-05
KR100521292B1 (ko) 2005-10-17
CN1515572A (zh) 2004-07-28
JP2000514096A (ja) 2000-10-24
KR20010012623A (ko) 2001-02-26
HUP0002754A2 (hu) 2001-06-28
AP9901688A0 (en) 1999-12-31
JP3150711B2 (ja) 2001-03-26
PL189527B1 (pl) 2005-08-31
HN1998000071A (es) 1999-03-19
DK0983271T3 (da) 2004-05-10
AR059120A2 (es) 2008-03-12
IS2207B (is) 2007-02-15
CN1263529A (zh) 2000-08-16
AU739953B2 (en) 2001-10-25
HRP980265A2 (en) 1999-02-28
AP2009A (en) 2009-06-26
ZA984085B (en) 2000-01-26
SK156199A3 (en) 2000-07-11
JP2000327679A (ja) 2000-11-28
TR199902810T2 (xx) 2000-02-21
BG103959A (en) 2000-12-29
GB2348202B (en) 2001-08-08
PT983271E (pt) 2004-07-30
YU59599A (fr) 2002-08-12
SI0983271T1 (en) 2004-06-30
UA56231C2 (uk) 2003-05-15
SK285159B6 (sk) 2006-07-07
MA26498A1 (fr) 2004-12-20
US6294540B1 (en) 2001-09-25
EP0983271B1 (fr) 2004-02-18
IL132793A0 (en) 2001-03-19
EG23836A (en) 2007-10-02
SA98190179B1 (ar) 2006-08-15
HU226563B1 (en) 2009-04-28
NZ510622A (en) 2002-04-26
GB0010222D0 (en) 2000-06-14
CN1150194C (zh) 2004-05-19
BRPI9809126B8 (pt) 2021-07-06
BRPI9809126B1 (pt) 2018-02-06
EA199900944A1 (ru) 2000-06-26
WO1998052949A1 (fr) 1998-11-26
RS49655B (sr) 2007-09-21
IL132793A (en) 2006-10-31

Similar Documents

Publication Publication Date Title
TNSN98065A1 (fr) Un sel nouveau
CA2017025A1 (fr) Proteine de liaison ii du facteur de necrose des tumeurs, sa purification et les anticorps diriges contre elle
FR2737971B1 (fr) Utilisation de la vitamine c ou de ses derives ou analogues pour stimuler la synthese de l'elastine cutanee
MY121201A (en) Pharmaceutical emulsion.
MA22922A1 (fr) Procede pour la preparation de nouveaux composes .
IT1269826B (it) Uso di antagonisti degli oppiacei e di sali di calcio per la preparazione di medicamenti per il trattamento di forme patologiche endorfino-mediate
IT8819213A0 (it) Procedimento e dispositivo per la realizzazione di mescole di caucciu'.
EP1210941A3 (fr) Compositions pharmaceutiques contenant le ritonavir (ABT-538) associé à l'indinavir (MK-639) et son utilisation pour le traitement du SIDA
NO995006L (no) Nye forbindelser
MA21645A1 (fr) Procede pour la preparation de nouveaux derives d'rtemisinine.
NL300109I1 (nl) Kristalmodificatie van CDCH, werkwijze voor de bereiding ervan en van farmaceutische preparaten die deze modificaties bevatten.
IL111674A0 (en) 5,6-Dihydropyrone derivatives and pharmaceutical compositions containing them
MA23922A1 (fr) Procede pour la preparation de nouveaux composes monocycliques de b-lactame et de medicament les contenant
EP0350690A3 (fr) Neutralisation des propriétés toxiques in vitro et in vivo du TNF-alfa par anticorps monoclonaux et fragments dérivés
MA22955A1 (fr) Procede pour la preparation de nouveaux composes .
MA21802A1 (fr) Procede pour la preparation du sel disodique de cefodizime .
IL111673A (en) 5,6-Dihydropyrone derivatives and pharmaceutical compositions containing them
DE69420229D1 (de) Pharmazeutische Zusammensetzung zur Behandlung von AIDS
RU95112519A (ru) (3,4-ди-фторфенокси)метил оксиран и способ его получения
MA24214A1 (fr) Procede pour la preparation de nouveaux composes et pour la preparation de compositions pharmaceutiques les contenant
NO872671D0 (no) 4-benzyloksy-3-pyrrolin-2-on-1-yl-acetamid, fremstilling og anvendelse derav.
MA22927A1 (fr) Procede pour la preparation de nouveaux composes.
EP0780472A3 (fr) Protéines de stress
FR2620021B1 (fr) Clou centro-medullaire endobloque pour le traitement de fractures d'os longs
FR2625651B1 (fr) Procede d'elimination de l'amertume d'hydrolysats de proteines et produit obtenu